0000000001080348

AUTHOR

S Saxena

showing 3 related works from this author

Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study

2021

ObjectivesStudies have demonstrated high rates of mortality in people with proximal femoral fracture and SARS-CoV-2, but there is limited published data on the factors that influence mortality for clinicians to make informed treatment decisions. This study aims to report the 30-day mortality associated with perioperative infection of patients undergoing surgery for proximal femoral fractures and to examine the factors that influence mortality in a multivariate analysis.SettingProspective, international, multicentre, observational cohort study.ParticipantsPatients undergoing any operation for a proximal femoral fracture from 1 February to 30 April 2020 and with perioperative SARS-CoV-2 infec…

Malemedicine.medical_specialty2474Multivariate analysisMORTALITY-RATEShipSURGERYSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MULTICENTERCOVIDSurg Collaborative1117 Public Health and Health ServicesCohort StudiesMedicine General & InternalInternal medicineGeneral & Internal MedicinemedicineDementiaHumans1506Prospective StudiesAged 80 and overCOMPLICATIONSScience & TechnologyHIP-FRACTURESbusiness.industryHip FracturesSARS-CoV-2RCOVID-191103 Clinical SciencesGeneral MedicineFemoral fracturePerioperativemedicine.diseaseHeart failuretrauma managementMedicineSurgery1737businessLife Sciences & BiomedicineFemoral FracturesKidney diseaseCohort study1199 Other Medical and Health SciencesBMJ Open
researchProduct

Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study…

2021

Background Documentation of patterns and long-term trends in mortality in young people, which reflect huge changes in demographic and social determinants of adolescent health, enables identification of global investment priorities for this age group. We aimed to analyse data on the number of deaths, years of life lost, and mortality rates by sex and age group in people aged 10–24 years in 204 countries and territories from 1950 to 2019 by use of estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. Methods We report trends in estimated total numbers of deaths and mortality rate per 100 000 population in young people aged 10–24 years by age group (10–14 y…

MaleJoves -- MortalitatADOLESCENT HEALTHCHILDRENSocioeconomic FactorGlobal Burden of DiseaseRA0421Cause of DeathMedicineYoung adultChild11 Medical and Health SciencesCause of deatheducation.field_of_studyAdolescent; Age Distribution; Cause of Death; Child; Female; Global Burden of Disease; Humans; Male; Mortality; Sex Distribution; Socioeconomic Factors; Young AdultMortality ratePublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineArticlesHälsovetenskaperMIDDLE-INCOMEFemaleMENTAL-HEALTHAdolescent healthINTERVENTIONSHumanSUICIDEAdolescentTotal fertility ratePopulationAdolescent HealthAdolescents -- MortalitatYoung AdultAge DistributionGeneral & Internal MedicineHealth SciencesHumansQUALITY:Medicine [Science]Social determinants of healthINCOME COUNTRIESMortalitySex Distributioneducationbusiness.industryTRENDSFolkhälsovetenskap global hälsa socialmedicin och epidemiologiYears of potential life lostSocioeconomic FactorsINJURIESbusinessDemographyLancet
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct